Biologic persistance rates consistently lower in women vs men with PsA. 52% vs 62% @ 1 year. Some statistically significant, but really it is a consistent message across drugs. We urgently need research on the reasons. Abstr#0779 #ACR23 @RheumNow https://t.co/Kfk3k3LJ44 https://t.co/SmiOnt7D4d

Risk factor for 1st Thrombosis in OB APS Ab#0115 #ACR23 @RheumNow 186 OAPS pts, followed mean 5.4 yrs. 11 thrombotic events Risk factors: Triple pos APS Abs (OR 11.6), hypocomplementemia (OR 9) Low dose Aspirin (OR 0.14), HCQ (OR 0.11) reduced thrombosis #ACRBest https://t.co/y4KaEAZzA7

🆕 Imaging modality: MSOT multispectral optoacoustic tomography Findings PsA enthesis -Hyperemia ↗️ oxygenation So2 and Hboxy -Reduction Collagen concentration -Lipids substitution But surprise PSO pts display similar signs despite abs of symptoms! @RheumNow ABST0750 #ACR23 https://t.co/qWMvmIRd7j

#ACR23 Convergence Preview https://t.co/oCdYnS1HdC https://t.co/A6klTchrrG

• ACR Convergence Preview (11.10.2023) | RheumNow

FAPα possible therapeutic biomarker target of pathogenic fibroblasts. #ACR23 Abs 0802 demonstrates potential therapeutic efficacy of fibroblast-targeted immunotherapy as a novel treatment in inflammatory disease. https://t.co/ZGUfC6PZxa @rheumnow https://t.co/jj9BeuvTuc

Abs#518 @RheumNow #ACR23 Deodhar: TOFA in AS, by b/l CRP levels 30% nml CRP (<5 mg/L) v 70% Elevated At wk 12, TOFA >> PBO regardless of b/l CRP Difference in response: greater in pts w elevated CRP Safety rates: elev. CRP c/w PBO, but nml CRP had trend of high AEs for tofa v PBO https://t.co/b9NRNkU8ub

Are Long-term NSAIDs safe in AS? Ab#0528 #ACR23 @RheumNow 19,775 AS pts vs 59,325 controls. Incidence of 16.9, 13.8 per 1,000 person-yrs, respectively Long-term use of NSAIDs increased risk of CVD in non-AS control (aHR 1.64), but did NOT in AS pts (aHR 1.06)

Differences in #glucocorticoid dosing. In #lupus #nephritis less steroids are the same as high dose steroids. Placebo arms of pooled data from #LN #RCTs. Less is equal! #ACRbest #ACR2023 ⁦@RheumNow⁩ ⁦@ACRheum⁩ abst0781 High dose steroids tended to have lower MMF doses https://t.co/XwTlsy4xKE

Plasma MMPs and RA-ILD. Strong association MMPs 7 & 9 with prevalent RA-ILD. Abstr#0770 #ACR23 @RheumNow https://t.co/5qWeK3lAly https://t.co/SyZY2OhcbH

2 yrs extension of DRESS-PS study 100+ pts w/ PsA and AxSPA -70% LDA state in both Ctrl & Intervention gps -strong recovery after relapse No difference efficacy protocolized & routine care tapering but inferior TNFi use (52 vs. 77%) in Intervention gp @RheumNow #ACR23 ABST0775 https://t.co/V2DqCjT0w3

#ACR23 IV secukinumab vs placebo at 52 Weeks @RheumNow https://t.co/4zQa37tN4l

Abs#0608 #ACR23 @RheumNow Cenerimod: sphigosine 1-phos (S1P) 1 receptor modulator for SLE P2 CARE Study 51% of pts had high IFN1 sign., ass w/ high dsDNA Cenerimod 4 mg: decreased dsDNA and IFN-a protein at 6 mo vs b/l In high IFN pts, 4 mg Cen: decrease SLEDAI, SRI-4

Abs#595 #ACR23 @RheumNow R Furie on 4 yr TULIP-LTE pts with b/l renal involvement 33% on anifrolumab continued to wk 208 vs PBO 6% Renal improvement at w208 in 9/10 pts, vs no avail PBO data Conclusion: more Anifrolumab pts remained in study & reached SLEDAI-2K renal improvement

Cowley et al @sharoncowley01 Subclinical GCA in 17.5% with new PMR. Males with higher ESR more likely to have subclinical GCA. Subclinical GCA more axillary artery. Abstr#0747 #ACR23 #ACRbest @RheumNow https://t.co/CghmX1TKpf https://t.co/MJawtslLud